
Opinion|Videos|December 2, 2024
SGLT2 inhibitors, RAAS inhibitors, nsMRAs, & GLP-1 receptor Agonists
Key Takeaways
- SGLT2 inhibitors reduce glucose reabsorption, providing renal and cardiovascular benefits in CKD management for type 2 diabetes patients.
- RAAS inhibitors target the renin-angiotensin-aldosterone system, reducing blood pressure and proteinuria, slowing CKD progression.
Panelists discuss how SGLT2 inhibitors, RAAS inhibitors, and GLP-1 receptor agonists differ in their treatment of chronic kidney disease (CKD) in patients with type 2 diabetes, along with strategies for managing hyperkalemia in patients to help them resume their treatment course.
Advertisement
- How do SGLT2 inhibitors, RAAS inhibitors, and GLP-1 receptor agonists differ in their treatment of CKD in patients with type 2 diabetes?
- Discuss your approach for patients who experience hyperkalemia during treatment. What strategies do you use to help them get back on their treatment course?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Rethinking “Type 2”: Inside the 2026 AACE Diabetes Classification Algorithm
2
VIASKIN Peanut Patch Efficacy Holds in Kids With Atopic Comorbidities
3
Fezolinetant Shows No CNS Safety Signal in Pooled Analysis of 3100 Women, With Marla Shapiro, CM
4
CAPTAIN-T2D: Interim Results Display High Cortisol Prevalence in Difficult-to-Control T2D
5
























































